<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654498</url>
  </required_header>
  <id_info>
    <org_study_id>248.630</org_study_id>
    <nct_id>NCT00654498</nct_id>
  </id_info>
  <brief_title>Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared
      to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of &quot;Much Improved&quot; and &quot;Very Much Improved&quot;</measure>
    <time_frame>6 weeks of treatment</time_frame>
    <description>CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of IRLS Responders</measure>
    <time_frame>6 weeks of treatment</time_frame>
    <description>responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patient Global Impression(PGI) Responders</measure>
    <time_frame>6 weeks of treatment</time_frame>
    <description>PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of &quot;much better&quot; or &quot;very much better&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised &gt;10</measure>
    <time_frame>week 6 of treatment</time_frame>
    <description>The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 (&quot;none/Not at all&quot;) to 10 (&quot;very severe&quot;) for the severity of RLS during the night.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 (&quot;none/Not at all&quot;) to 10 (&quot;very severe&quot;) for the severity of RLS during the rest at day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 (&quot;none/Not at all&quot;) to 10 (&quot;very severe&quot;) for the severity of RLS during the activity at day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 (&quot;none/Not at all&quot;) to 10 (&quot;very severe&quot;) for the intensity of tiredness and sleepiness at day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in Visual Analogue Scales (VAS)</measure>
    <time_frame>Baseline and 6 weeks of treatment</time_frame>
    <description>VAS is for assessment of RLS-associated pain. The patient was asked &quot;How severe was your RLS associated pain in legs or arms during the past week?&quot;. No pain:0; very worst pain:10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Pramipexole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4 weeks of individual dose titration as for the investigational product, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <arm_group_label>Pramipexole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent consistent with International Conference on Harmonisation
             (ICH) / Good Clinical Practice (GCP) and local legislation given prior to any study
             procedures.

          2. Ability and willingness to comply with study treatment regimen and to attend study
             assessments.

          3. Male or female out-patients aged 18-80 years.

          4. Diagnosis of idiopathic Restless Legs Syndrome (IRLS) according to the clinical
             Restless Legs Syndrome (RLS) criteria of the International Restless Legs Syndrome
             Study Group (IRLSSG)

             All four criteria must be present to fulfil the diagnosis of RLS:

               -  An urge to move the legs, usually accompanied or caused by uncomfortable and
                  unpleasant sensations in the legs. (Sometimes the urge to move is present without
                  the uncomfortable sensations and sometimes the arms or other body parts are
                  involved in addition to the legs).

               -  The urge to move or unpleasant sensations begin or worsen during periods of rest
                  or inactivity such as lying or sitting.

               -  The urge to move or unpleasant sensations are partially or totally relieved by
                  movement, such as walking or stretching, at least as long as the activity
                  continues.

               -  The urge to move or unpleasant sensations are worse in the evening or night than
                  during the day or only occur in the evening or night. (When symptoms are very
                  severe, the worsening at night may not be noticeable but must have been
                  previously present).

          5. Restless Legs Syndrome (RLS)rating scale for severity total score &gt;15.

          6. Restless Legs Syndrome (RLS) symptoms present at least 2 to 3 days per week during the
             last 3 months.

        Exclusion Criteria:

          1. Women of child-bearing potential (i.e. premenopausal women, or postmenopausal women
             less than 2 years after last menses) who do not use during the clinical trial an
             adequate method of contraception such as: hormonal therapy (combined oral
             contraceptives, injectables, or subcutaneous implants), hormonal intrauterine devices,
             sexual abstinence, surgical sterilization of patient and/or partner, hysterectomy,
             bilateral ovariectomy or partners vasectomy

          2. Any woman of child-bearing potential not having a negative pregnancy test at screening

          3. Patients who are breastfeeding

          4. Concomitant or previous pharmacologically therapy of RLS as follows:

               -  Any intake of levodopa within 5 days prior to baseline visit (V2)

               -  Any intake of dopamine agonists within 14 days prior to baseline visit (V2)

          5. Current (less than 14 days before treatment with trial medication or concomitant)
             treatment with medication or dietary supplements, which could significantly influence
             RLS symptoms, e.g. dopaminergic (other than levodopa or dopamine agonists) or
             anti-dopaminergic drugs, non-selective Monoamine Oxidase (MAO) inhibitors,
             sympathomimetics, neuroleptics, anti-depressants, hypnotics, any benzodiazepines,
             antiepileptics, opioids, clonidine, magnesium, ferrous salts, Folic acid, vitamin B12,
             antihistaminics, lithium, metoclopramide or Withdrawal symptoms caused by stopping any
             of the drugs above

          6. Confirmed diagnose of diabetic nephropathy or clinically significant renal disease

          7. Creatinine higher than upper limit of normal (ULN) at screening

          8. Clinical significant hepatic disease or Alanine aminotransferase (ALT) &gt;2 times the
             upper limit of normal range at screening

          9. Clinical or laboratory signs of microcytic anaemia, or ferritin in serum below the
             lower bound of the reference range

         10. Any of the following lab results at screening:

               -  Basal Thyroid Stimulating Hormone (TSH), T3 or T4 clinically significantly (at
                  the investigators discretion) out of normal range at screening (if not caused by
                  substitution therapy according the investigators opinion)

               -  Patients with any clinically significant abnormalities in laboratory parameters
                  at screening at the investigators discretion

         11. Other clinically significant metabolic-endocrine, haematological, gastro-intestinal
             disease or pulmonary disease (such as severe COPD). Poorly controlled cardiovascular
             disease (including hypotension and severe coronary artery disease)

         12. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical,
             neuro-logical examination, myelopathy or multiple sclerosis or any other neurological
             disease, with potential to secondarily cause RLS symptoms

         13. Presence of any other sleep disorder, such as, Rapid Eye Movement (REM) sleep
             behaviour disorder, narcolepsy or sleep apnoea syndrome

         14. History of Schizophrenia or any psychotic disorder, history of mental disorders due to
             a general medical condition or any present axis I psychiatric disorder according to
             Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV)
             requiring any medical therapy

         15. History of alcohol abuse or drug addiction within the last 2 years before screening

         16. Participation in a drug study within two months prior to the start of this study

         17. History of or clinical signs for any form of epilepsy or seizures apart from fever
             related seizures in early childhood

         18. History of or clinical signs of malign neoplasm

         19. Patients on a shift-work-schedule, or who are otherwise unable to follow a regular
             sleep-wake cycle enabling use of study medication at times indicated

         20. Any other conditions that in the opinion of the investigator would interfere with the
             evaluation of the results or constitute a health hazard for the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>248.630.04 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.05 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.06 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.07 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.08 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.15 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.14 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.10 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.09 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.12 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.01 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.02 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.03 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.16 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.13 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.630.11 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xian, Shanxi Province</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <results_first_submitted>December 18, 2009</results_first_submitted>
  <results_first_submitted_qc>February 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2010</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pramipexole</title>
          <description>4 weeks of individual dose titration starting with 0.125 mg pramipexole, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1 tablet (Pramipexole 0.125 mg matching placebo tablet), or 1 or 2 or 3 tablets (Pramipexole 0.25 mg matching placebo tablet), once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set, all randomized patients that received treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Pramipexole</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.46" spread="11.88"/>
                    <measurement group_id="B2" value="56.86" spread="11.89"/>
                    <measurement group_id="B3" value="56.6" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).</title>
        <description>The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), All patients randomized, treated, having data for primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).</title>
          <description>The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).</description>
          <population>Full Analysis Set (FAS), All patients randomized, treated, having data for primary endpoint</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.87" spread="0.66"/>
                    <measurement group_id="O2" value="-11.35" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.58</ci_lower_limit>
            <ci_upper_limit>-2.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of &quot;Much Improved&quot; and &quot;Very Much Improved&quot;</title>
        <description>CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.</description>
        <time_frame>6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of &quot;Much Improved&quot; and &quot;Very Much Improved&quot;</title>
          <description>CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.</description>
          <units>Proportion of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.819"/>
                    <measurement group_id="O2" value="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>test stratified by centre</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of IRLS Responders</title>
        <description>responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.</description>
        <time_frame>6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of IRLS Responders</title>
          <description>responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.</description>
          <units>Proportion of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.738"/>
                    <measurement group_id="O2" value="0.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>test stratified by centre</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patient Global Impression(PGI) Responders</title>
        <description>PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of &quot;much better&quot; or &quot;very much better&quot;.</description>
        <time_frame>6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patient Global Impression(PGI) Responders</title>
          <description>PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of &quot;much better&quot; or &quot;very much better&quot;.</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.686"/>
                    <measurement group_id="O2" value="0.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>test stratified by centre</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised &gt;10</title>
        <description>The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.</description>
        <time_frame>week 6 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised &gt;10</title>
          <description>The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.</description>
          <units>Proportion of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.108"/>
                    <measurement group_id="O2" value="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1386</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales</title>
        <description>RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales</title>
          <description>RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.52" spread="0.21"/>
                    <measurement group_id="O2" value="-3.04" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.14</ci_lower_limit>
            <ci_upper_limit>-0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.</title>
        <description>RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.</title>
          <description>RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="0.21"/>
                    <measurement group_id="O2" value="-3.53" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.99</ci_lower_limit>
            <ci_upper_limit>-0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.</title>
        <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the severity of RLS during the night.</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.</title>
          <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the severity of RLS during the night.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.68" spread="0.21"/>
                    <measurement group_id="O2" value="-3.32" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>-0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.</title>
        <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the severity of RLS during the rest at day.</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.</title>
          <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the severity of RLS during the rest at day.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="0.17"/>
                    <measurement group_id="O2" value="-2.36" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0402</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale</title>
        <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the severity of RLS during the activity at day.</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale</title>
          <description>RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the severity of RLS during the activity at day.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.12"/>
                    <measurement group_id="O2" value="-0.61" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0771</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale</title>
        <description>RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the intensity of tiredness and sleepiness at day.</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale</title>
          <description>RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 (“none/Not at all”) to 10 (“very severe”) for the intensity of tiredness and sleepiness at day.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="0.16"/>
                    <measurement group_id="O2" value="-2.25" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.20</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in Visual Analogue Scales (VAS)</title>
        <description>VAS is for assessment of RLS-associated pain. The patient was asked “How severe was your RLS associated pain in legs or arms during the past week?”. No pain:0; very worst pain:10</description>
        <time_frame>Baseline and 6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramipexole</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in Visual Analogue Scales (VAS)</title>
          <description>VAS is for assessment of RLS-associated pain. The patient was asked “How severe was your RLS associated pain in legs or arms during the past week?”. No pain:0; very worst pain:10</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.5"/>
                    <measurement group_id="O2" value="3.9" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pramipexole</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

